Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes.

Original languageEnglish (US)
Pages (from-to)306-320
Number of pages15
JournalClinical Pharmacology and Therapeutics
Volume92
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Eosinophilic Esophagitis
Gastroparesis
Short Bowel Syndrome
Irritable Bowel Syndrome
Gastrointestinal Diseases
Biological Factors
Celiac Disease
Constipation
Gastroesophageal Reflux
Ulcerative Colitis
Inflammatory Bowel Diseases
Crohn Disease
Diarrhea
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{76d69fc2e4a9400f81a6913169ddbe04,
title = "Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases",
abstract = "Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes.",
author = "Katzka, {David A} and {Loftus, Jr}, {Edward Vincent} and Michael Camilleri",
year = "2012",
month = "9",
doi = "10.1038/clpt.2012.77",
language = "English (US)",
volume = "92",
pages = "306--320",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases

AU - Katzka, David A

AU - Loftus, Jr, Edward Vincent

AU - Camilleri, Michael

PY - 2012/9

Y1 - 2012/9

N2 - Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes.

AB - Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84865424516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865424516&partnerID=8YFLogxK

U2 - 10.1038/clpt.2012.77

DO - 10.1038/clpt.2012.77

M3 - Article

VL - 92

SP - 306

EP - 320

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -